Hepatitis E VLP Towards Cancer Cell Targeting and Drug Delivery
In an interview by MedGadget.com, graduate student Marie Stark and post-doctoral scientist Dr. Prasida Holla explain the conceptual fundamentals of Hepatitis E Virus-Like Particle (HEV-VLP), an immunogen and drug delivery platform. Utilization of this non-infectious carrier towards mucosal drug delivery, is an innovative approach towards cancer drug delivery, specifically addressed towards the active cancerous tissue, resulting in eradication of chronic and acute infection. The potency and effectiveness of the patented technology of HEV-VLPs has been carefully tested in previous years by Dr. Holland Cheng’s laboratory based in UC Davis. The Hepatitis E Virus capsid structure evolved for stability in the human body and thus can be used for efficient host cell binding and drug delivery. This revolutionary finding is a major competitor for mucosal drug/immunogen delivery.
Structural Modularity in Vaccine Platform Design
Hepatitis E virus (HEV) is a feco-orally transmitted, hepatotropic, non-enveloped virus. Insect cell expressed virus-like particles (VLPs) mimic the virus in terms of their stability and integrity in gut environment1 and at extremes of temperature. Additionally, the tertiary structure of the capsid protein is organized such that extensive modification of the surface-protrusion forming domain (P) does not affect the ability of the dimeric building blocks to assemble into VLPs.